ClinicalTrials.gg

Program

Citrulline

Also written as “L-citrulline”, “L-citrulline tablets, 1000 mg” and “L-Citrulline”.

Its studies are mostly in Vaso-Occlusive Crises · Heart Septal Defects, Ventricular · Acute Lung Injury · Respiratory Insufficiency · Heart Septal Defects, Atrial, led by 2 companies.

Furthest: phase 3, since Jun 7, 20069 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Asklepion Pharmaceuticals71 open or runningphase 3since Jun 7, 2006Jun 7, 2006Jun 2027phase 3 · NCT06989567
Angiogenix20 open or runningphase 2since Jul 10, 2006Jun 21, 2006none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 7, 2006First study: phase 3 study in Heart Defects, CongenitalNew to Asklepion PharmaceuticalsAsklepion Pharmaceuticals · NCT00335244 · 77 enrolled · United States
  2. Jun 21, 2006Angiogenix's first study: phase 1 study in Anemia, Sickle CellNew to AngiogenixAngiogenix · NCT00343954 · 12 enrolled · United States
  3. Jul 10, 2006Phase 2 study in Peripheral Arterial DiseaseAngiogenix · NCT00351286 · 160 enrolled · Russian Federation
  4. May 6, 2010Phase 2 study in Heart Septal Defects, AtrialAsklepion Pharmaceuticals · NCT01120964 · 22 enrolled · United States
  5. Aug 23, 2016Phase 3 study in Acute Lung InjuryAsklepion Pharmaceuticals · NCT02891837 · 189 enrolled · United States, Austria, Germany and more
  6. Sep 17, 2020Phase 2 study in Respiratory InsufficiencyAsklepion Pharmaceuticals · NCT04570384 · 65 enrolled · United States
  7. Mar 18, 2021Phase 2 study in Acute Vaso Occlusive Crisis (VOC)Asklepion Pharmaceuticals · NCT04852172 · 30 enrolled · United States
  8. Jan 24, 2022Phase 3 study in Heart Septal Defects, VentricularAsklepion Pharmaceuticals · NCT05253209 · 64 enrolled · United States
  9. May 8, 2025Phase 3 study in Anemia, Sickle CellAsklepion Pharmaceuticals · NCT06989567 · 120 planned · United States

Ahead

  1. Jun 2027Primary completion: phase 3 study in Anemia, Sickle CellAsklepion Pharmaceuticals · NCT06989567

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06989567Anemia, Sickle Cell · United States3Not yet recruitingAsklepion PharmaceuticalsJun 2027120
NCT05253209Heart Septal Defects, Ventricular · United States3TerminatedAsklepion PharmaceuticalsMay 10, 202464
NCT04852172Acute Vaso Occlusive Crisis (VOC) · United States2TerminatedAsklepion PharmaceuticalsFeb 29, 202430
NCT04570384Respiratory Insufficiency · United States2CompletedAsklepion PharmaceuticalsAug 30, 202165
NCT02891837Acute Lung Injury · United States, Austria, Germany and more3CompletedAsklepion PharmaceuticalsJun 2019189
NCT01120964Heart Septal Defects, Atrial · United States2CompletedAsklepion PharmaceuticalsApr 201222
NCT00351286Peripheral Arterial Disease · Russian Federation2UNKNOWNAngiogenix160
NCT00343954Anemia, Sickle Cell · United States1UNKNOWNAngiogenix12
NCT00335244Heart Defects, Congenital · United States3CompletedAsklepion PharmaceuticalsDec 200977

How it is read

Names in the registry

  • “L-citrulline”, 5 entries
  • “L-citrulline tablets, 1000 mg”, 2 entries
  • “L-Citrulline”, 1 entry
  • “Intravenous L-Citrulline”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.